Wells Fargo & Company Bio Cardia, Inc. Transaction History

Wells Fargo & Company

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$0.38 - $0.68 $4 - $7	11 Added 11.22%	109 $0
Q4 2023 Feb 09, 2024	BUY	$0.37 - $1.07 $1 - $5	5 Added 5.38%	98 $0
Q3 2023 Nov 13, 2023	SELL	$0.37 - $2.85 $3 - $25	-9 Reduced 8.82%	93 $0
Q2 2023 Aug 15, 2023	BUY	$1.52 - $2.8 $22 - $42	15 Added 17.24%	102 $0
Q1 2023 May 12, 2023	BUY	$1.87 - $2.54 $3 - $5	2 Added 2.35%	87 $0
Q4 2022 Feb 13, 2023	BUY	$1.61 - $32.1 $3 - $64	2 Added 2.41%	85 $0
Q3 2022 Nov 14, 2022	BUY	$0.24 - $30.3 $1 - $151	5 Added 6.41%	83 $0
Q2 2022 Aug 12, 2022	BUY	$17.7 - $32.55 $141 - $260	8 Added 11.43%	78 $0
Q1 2022 May 16, 2022	BUY	$21.3 - $39.0 $21 - $39	1 Added 1.45%	70 $0
Q3 2021 Nov 15, 2021	SELL	$42.6 - $58.65 $681 - $938	-16 Reduced 18.82%	69 $0
Q2 2021 Aug 16, 2021	BUY	$48.9 - $74.85 $537 - $823	11 Added 14.86%	85 $0
Q1 2021 May 13, 2021	BUY	$51.3 - $78.15 $513 - $781	10 Added 15.63%	74 $0
Q4 2020 Feb 09, 2021	BUY	$28.8 - $100.5 $1,094 - $3,819	38 Added 146.15%	64 $0
Q3 2020 Nov 05, 2020	BUY	$30.75 - $42.0 $61 - $84	2 Added 8.33%	26 $0
Q1 2020 May 14, 2020	BUY	$33.0 - $85.2 $792 - $2,044	24 New	24 $0

Ticker BCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,758,200
Market Cap $41.2M
Description
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and allogeneic cell therapy for cardiac and pulmonary di...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.